SCHEMBL17324209

SCHEMBL17324209

COC(=O)c1cc2cc(CNC(=O)c3cc(NC(=O)c4ccc(CN5CCN(C)CC5)c(CF)c4)ccc3C)cnc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 10/20 0.46
▸ BRAF P15056 9/20 0.46
▸ ABL1 P00519 9/20 0.44
▸ PDGFRA P16234 2/20 0.44
▸ FGFR1 P11362 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ FLT3 P36888 1/20 0.44
▸ LRRK2 Q5S007 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ KIT P10721 2/20 0.43
▸ SRC P12931 2/20 0.43
▸ LCK P06239 1/20 0.43
▸ FYN P06241 1/20 0.43
▸ YES1 P07947 1/20 0.43
▸ LYN P07948 1/20 0.43
▸ HCK P08631 1/20 0.43
▸ BCR P11274 1/20 0.43
▸ FRK P42685 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15860005 0.91 BRAF (0.56) EGFRBRAFABL1PDGFRAFGFR1
SCHEMBL15860013 0.90 EGFR (0.50) EGFRBRAFABL1PDGFRAFLT3
SCHEMBL17324268 0.88 CSK (0.48) EGFRBRAFABL1PDGFRASRC
SCHEMBL17324148 0.83 CHRM3 (0.42) EGFRBRAFABL1SRC
SCHEMBL15859973 0.82 BRAF (0.59) EGFRBRAFABL1PDGFRAFGFR1
SCHEMBL18403050 0.82 EGFR (0.46) EGFRBRAFABL1PDGFRAFGFR1
SCHEMBL15860029 0.81 KIT (0.51) EGFRBRAFABL1PDGFRAFGFR1
SCHEMBL18403051 0.81 CSK (0.49) EGFRBRAFABL1PDGFRAFGFR1
SCHEMBL13260700 0.81 ABL1 (0.56) EGFRBRAFABL1PDGFRAFLT3
SCHEMBL15860128 0.81 BRAF (0.60) EGFRBRAFABL1KITLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550772-B2 Azaindole derivatives as multi kinase inhibitors ORIBASE PHARMA (FR) 2017-01-24 — — US disclosed
US-20150353539-A1 AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS ORIBASE PHARMA (FR) 2015-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353539-A1 AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS MAP2K2, MAP2K5, MAP2K3 EGFR 1148/4885BRAF 74/4885ABL1 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback